Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials

Core Insights - Enveric Biosciences has made significant progress in the chemistry, manufacturing, and controls (CMC) development of its lead candidate, EB-003 [1] - The advancements include scaling production and preparing the drug for necessary regulatory activities [1] Company Developments - The company is focused on developing next-generation neuroplastogenic small molecules aimed at treating psychiatric and neurological disorders [1] - The progress in CMC development is a crucial step for the advancement of EB-003 [1]